Certain Plant-Derived Recombinant Human Serum Albumins (“rHSA”) and Products Containing Same; Notice of Institution of Investigation, 6916-6917 [2021-01439]
Download as PDF
<![CDATA[
6916
Federal Register / Vol. 86, No. 14 / Monday, January 25, 2021 / Notices
Certification of Plans, Specifications,
and Site; (2) Form HUD–92544,
Warranty of Completion of
Construction; (3) Form HUD–NPMA–
99–A, Subterranean Termite Protection
Builder’s Guarantee; and (4) Form
HUD–NPMA–99–B, New Construction
Subterranean Termite Service Record.
These forms are currently required by
FHA for maximum financing for FHA’s
Title II Single Family forward mortgage
programs and will align both the reverse
and forward mortgage programs to
ensure the property meet’s FHA’s
minimum property standards while
ensuring the home is safe, sound, and
secure for the HECM borrower.
Respondents (i.e., affected public):
Business or other for profit.
Estimated Number of Respondents:
2,375.
Estimated Number of Responses:
59,375.
Frequency of Response: Occasionally.
Average Hours per Response: 2.54
hours.
Total Estimated Burdens: 116,398.75.
B. Solicitation of Public Comment
jbell on DSKJLSW7X2PROD with NOTICES
This notice is soliciting comments
from members of the public and affected
parties concerning the collection of
information described in Section A on
the following:
(1) Whether the proposed collection
of information is necessary for the
proper performance of the functions of
the agency, including whether the
information will have practical utility;
(2) The accuracy of the agency’s
estimate of the burden of the proposed
collection of information;
(3) Ways to enhance the quality,
utility, and clarity of the information to
be collected; and
(4) Ways to minimize the burden of
the collection of information on those
who are to respond: Including through
the use of appropriate automated
collection techniques or other forms of
information technology, e.g., permitting
electronic submission of responses.
(5) Ways to minimize the burden of
the collection of information on those
who are to respond, including the use
of automated collection techniques or
other forms of information technology.
HUD encourages interested parties to
submit comments in response to the
proposed changes.
Authority: Section 3507 of the Paperwork
Reduction Act of 1995, 44 U.S.C. Chapter 35.
Colette Pollard,
Department Reports Management Officer,
Office of the Chief Information Officer.
[FR Doc. 2021–01515 Filed 1–22–21; 8:45 am]
BILLING CODE 4210–67–P
VerDate Sep<11>2014
18:31 Jan 22, 2021
Jkt 253001
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–1238]
Certain Plant-Derived Recombinant
Human Serum Albumins (‘‘rHSA’’) and
Products Containing Same; Notice of
Institution of Investigation
International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that a
complaint was filed with the U.S.
International Trade Commission on
December 16, 2020, under section 337 of
the Tariff Act of 1930, as amended, on
behalf of Ventria Bioscience Inc. of
Junction City, Kansas. Supplements to
the complaint were filed on December
16, and 22, 2020. The complaint, as
supplemented, alleges violations of
section 337 based upon the importation
into the United States, the sale for
importation, and the sale within the
United States after importation of
certain plant-derived recombinant
human serum albumins (‘‘rHSA’’) and
products containing same by reason of
infringement of certain claims of U.S.
Patent No. 10,618,951 (‘‘the ’951
patent’’); and U.S. Patent No. 8,609,416
(‘‘the ’416 patent’’). The complaint
further alleges that an industry in the
United States exists as required by the
applicable Federal Statute. The
complaint also alleges violations of
section 337 based on the importation
into the United States, or in the sale of,
certain plant-derived recombinant
human serum albumins (‘‘rHSA’’) and
products containing same by reason of
false designation of origin, the threat or
effect of which is to destroy or
substantially injure an industry in the
United States.
The complainant requests that the
Commission institute an investigation
and, after the investigation, issue a
limited exclusion order and cease and
desist orders.
ADDRESSES: The complaint, except for
any confidential information contained
therein, may be viewed on the
Commission’s electronic docket (EDIS)
at https://edis.usitc.gov. For help
accessing EDIS, please email
EDIS3Help@usitc.gov. Hearing impaired
individuals are advised that information
on this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810. Persons
with mobility impairments who will
need special assistance in gaining access
to the Commission should contact the
Office of the Secretary at (202) 205–
2000. General information concerning
SUMMARY:
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
the Commission may also be obtained
by accessing its internet server at
https://www.usitc.gov.
FOR FURTHER INFORMATION CONTACT:
Pathenia M. Proctor, The Office of
Unfair Import Investigations, U.S.
International Trade Commission,
telephone (202) 205–2560.
SUPPLEMENTARY INFORMATION:
Authority: The authority for
institution of this investigation is
contained in section 337 of the Tariff
Act of 1930, as amended, 19 U.S.C.
1337, and in section 210.10 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.10 (2020).
Scope of Investigation: Having
considered the complaint, the U.S.
International Trade Commission, on
January 14, 2021, ordered that—
(1) Pursuant to subsection (b) of
section 337 of the Tariff Act of 1930, as
amended, an investigation be instituted
to determine:
(a) Whether there is a violation of
subsection (a)(1)(B) of section 337 in the
importation into the United States, the
sale for importation, or the sale within
the United States after importation of
certain products identified in paragraph
(2) by reason of infringement of one or
more of claims 1–3 and 11–13 of the
’951 patent and claims 1–3, 5–7, 10, 12,
18–20, and 22–25 of the ’416 patent; and
whether an industry in the United
States exists as required by subsection
(a)(2) of section 337; and
(b) Whether there is a violation of
subsection (a)(1)(A) of section 337 in the
importation into the United States, or in
the sale of, certain products identified
in paragraph (2) by reason of false
designation of origin.
(2) Pursuant to section 210.10(b)(1) of
the Commission’s Rules of Practice and
Procedure, 19 CFR 210.10(b)(1), the
plain language description of the
accused products or category of accused
products, which defines the scope of the
investigation, is: Plant-derived
recombinant human serum albumins
(‘‘rHSA’’) and products containing the
same, such as lyophilized powders and
liquid suspensions primarily containing
rHSA along with naturally-occurring
plant expression by-products, such as
plant heat shock proteins and/or plant
fatty acids, as well as cell culture media
supplements formulated with such
rHSA products.
(3) For the purpose of the
investigation so instituted, the following
are hereby named as parties upon which
this notice of investigation shall be
served:
(a) The complainant is: Ventria
Bioscience Inc., 2718 Industrial Drive,
Junction City, Kansas 66441.
E:\FR\FM\25JAN1.SGM
25JAN1
Federal Register / Vol. 86, No. 14 / Monday, January 25, 2021 / Notices
jbell on DSKJLSW7X2PROD with NOTICES
(b) The respondents are the following
entities alleged to be in violation of
section 337, and are the parties upon
which the complaint is to be served:
Wuhan Healthgen Biotechnology Corp.,
No. 666 Gaoxin Avenue, East Lake
High-Tech Development Zone,
Wuhan, China, 430075
ScienCell Research Laboratories, Inc.,
1610 Faraday Avenue, Carlsbad,
California 92008
Aspira Scientific, Inc., 521 Cottonwood
Drive, Suite 112, Milpitas, California
95035
eEnzyme LLC, 963 Featherstone Street,
Gaithersburg, Maryland 20879
(c) The Office of Unfair Import
Investigations, U.S. International Trade
Commission, 500 E Street SW, Suite
401, Washington, DC 20436; and
(4) For the investigation so instituted,
the Chief Administrative Law Judge,
U.S. International Trade Commission,
shall designate the presiding
Administrative Law Judge.
Responses to the complaint and the
notice of investigation must be
submitted by the named respondent in
accordance with section 210.13 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.13. Pursuant to
19 CFR 201.16(e) and 210.13(a), as
amended in 85 FR 15798 (March 19,
2020), such responses will be
considered by the Commission if
received not later than 20 days after the
date of service by the complainant of the
complaint and the notice of
investigation. Extensions of time for
submitting responses to the complaint
and the notice of investigation will not
be granted unless good cause therefor is
shown.
Failure of the respondent to file a
timely response to each allegation in the
complaint and in this notice may be
deemed to constitute a waiver of the
right to appear and contest the
allegations of the complaint and this
notice, and to authorize the
administrative law judge and the
Commission, without further notice to
the respondent, to find the facts to be as
alleged in the complaint and this notice
and to enter an initial determination
and a final determination containing
such findings, and may result in the
issuance of an exclusion order or a cease
and desist order or both directed against
the respondent.
INTERNATIONAL TRADE
COMMISSION
INTERNATIONAL TRADE
COMMISSION
[Investigation Nos. 701–TA–636 and 731–
TA–1470 (Final)]
Notice of Receipt of Complaint;
Solicitation of Comments Relating to
the Public Interest
Wood Mouldings and Millwork
Products From China; Revised
Schedule for the Subject
Investigations
United States International
Trade Commission.
AGENCY:
ACTION:
DATES:
Notice.
January 13, 2021.
FOR FURTHER INFORMATION CONTACT:
Keysha Martinez (202–205–2136), Office
of Investigations, U.S. International
Trade Commission, 500 E Street SW,
Washington, DC 20436. Hearingimpaired persons can obtain
information on this matter by contacting
the Commission’s TDD terminal on 202–
205–1810. Persons with mobility
impairments who will need special
assistance in gaining access to the
Commission should contact the Office
of the Secretary at 202–205–2000.
General information concerning the
Commission may also be obtained by
accessing its internet server (https://
www.usitc.gov). The public record for
these investigations may be viewed on
the Commission’s electronic docket
(EDIS) at https://edis.usitc.gov.
On August
12, 2020, the Commission established a
schedule for the conduct of the final
phase of the subject investigations (85
FR 54593, September 2, 2020). In light
of the federal holiday on January 20,
2021, the Commission is revising the
final comments deadline to no later than
10 a.m., January 21, 2021.
For further information concerning
this proceeding, see the Commission’s
notice cited above and the
Commission’s Rules of Practice and
Procedure, part 201, subparts A through
E (19 CFR part 201), and part 207,
subparts A and C (19 CFR part 207).
SUPPLEMENTARY INFORMATION:
Authority: These investigations are being
conducted under authority of title VII of the
Tariff Act of 1930; this notice is published
pursuant to § 207.21 of the Commission’s
rules.
By order of the Commission.
Issued: January 15, 2021.
Lisa Barton,
Secretary to the Commission.
By order of the Commission.
Issued: January 19, 2021.
William Bishop,
Supervisory Hearings and Information
Officer.
[FR Doc. 2021–01439 Filed 1–22–21; 8:45 am]
[FR Doc. 2021–01532 Filed 1–22–21; 8:45 am]
BILLING CODE 7020–02–P
BILLING CODE 7020–02–P
VerDate Sep<11>2014
18:31 Jan 22, 2021
Jkt 253001
6917
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that
the U.S. International Trade
Commission has received a complaint
entitled Certain Cellular
Communications Infrastructure
Systems, Components Thereof, and
Products Containing Same, DN 3525;
the Commission is soliciting comments
on any public interest issues raised by
the complaint or complainant’s filing
pursuant to the Commission’s Rules of
Practice and Procedure.
FOR FURTHER INFORMATION CONTACT: Lisa
R. Barton, Secretary to the Commission,
U.S. International Trade Commission,
500 E Street SW, Washington, DC
20436, telephone (202) 205–2000. The
public version of the complaint can be
accessed on the Commission’s
Electronic Document Information
System (EDIS) at https://edis.usitc.gov.
For help accessing EDIS, please email
EDIS3Help@usitc.gov.
General information concerning the
Commission may also be obtained by
accessing its internet server at United
States International Trade Commission
(USITC) at https://www.usitc.gov. The
public record for this investigation may
be viewed on the Commission’s
Electronic Document Information
System (EDIS) at https://edis.usitc.gov.
Hearing-impaired persons are advised
that information on this matter can be
obtained by contacting the
Commission’s TDD terminal on (202)
205–1810.
SUPPLEMENTARY INFORMATION: The
Commission has received a complaint
and a submission pursuant to § 210.8(b)
of the Commission’s Rules of Practice
and Procedure filed on behalf of
Ericsson Inc. and Telefonaktiebolaget
LM Ericsson on January 15, 2021. The
complaint alleges violations of section
337 of the Tariff Act of 1930 (19 U.S.C.
1337) in the importation into the United
States, the sale for importation, and the
sale within the United States after
importation of certain cellular
communications infrastructure systems,
components thereof, and products
containing same. The complaint names
as respondents: Samsung Electronics
Co. Ltd. of Korea and Samsung
Electronics America, Inc. of Ridgefield
Park, NJ. The complainant requests that
the Commission issue a limited
SUMMARY:
E:\FR\FM\25JAN1.SGM
25JAN1
]]>Agencies
[Federal Register Volume 86, Number 14 (Monday, January 25, 2021)]
[Notices]
[Pages 6916-6917]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-01439]
=======================================================================
-----------------------------------------------------------------------
INTERNATIONAL TRADE COMMISSION
[Investigation No. 337-TA-1238]
Certain Plant-Derived Recombinant Human Serum Albumins (``rHSA'')
and Products Containing Same; Notice of Institution of Investigation
AGENCY: International Trade Commission.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that a complaint was filed with the
U.S. International Trade Commission on December 16, 2020, under section
337 of the Tariff Act of 1930, as amended, on behalf of Ventria
Bioscience Inc. of Junction City, Kansas. Supplements to the complaint
were filed on December 16, and 22, 2020. The complaint, as
supplemented, alleges violations of section 337 based upon the
importation into the United States, the sale for importation, and the
sale within the United States after importation of certain plant-
derived recombinant human serum albumins (``rHSA'') and products
containing same by reason of infringement of certain claims of U.S.
Patent No. 10,618,951 (``the '951 patent''); and U.S. Patent No.
8,609,416 (``the '416 patent''). The complaint further alleges that an
industry in the United States exists as required by the applicable
Federal Statute. The complaint also alleges violations of section 337
based on the importation into the United States, or in the sale of,
certain plant-derived recombinant human serum albumins (``rHSA'') and
products containing same by reason of false designation of origin, the
threat or effect of which is to destroy or substantially injure an
industry in the United States.
The complainant requests that the Commission institute an
investigation and, after the investigation, issue a limited exclusion
order and cease and desist orders.
ADDRESSES: The complaint, except for any confidential information
contained therein, may be viewed on the Commission's electronic docket
(EDIS) at https://edis.usitc.gov. For help accessing EDIS, please email
[email protected]. Hearing impaired individuals are advised that
information on this matter can be obtained by contacting the
Commission's TDD terminal on (202) 205-1810. Persons with mobility
impairments who will need special assistance in gaining access to the
Commission should contact the Office of the Secretary at (202) 205-
2000. General information concerning the Commission may also be
obtained by accessing its internet server at https://www.usitc.gov.
FOR FURTHER INFORMATION CONTACT: Pathenia M. Proctor, The Office of
Unfair Import Investigations, U.S. International Trade Commission,
telephone (202) 205-2560.
SUPPLEMENTARY INFORMATION:
Authority: The authority for institution of this investigation is
contained in section 337 of the Tariff Act of 1930, as amended, 19
U.S.C. 1337, and in section 210.10 of the Commission's Rules of
Practice and Procedure, 19 CFR 210.10 (2020).
Scope of Investigation: Having considered the complaint, the U.S.
International Trade Commission, on January 14, 2021, ordered that--
(1) Pursuant to subsection (b) of section 337 of the Tariff Act of
1930, as amended, an investigation be instituted to determine:
(a) Whether there is a violation of subsection (a)(1)(B) of section
337 in the importation into the United States, the sale for
importation, or the sale within the United States after importation of
certain products identified in paragraph (2) by reason of infringement
of one or more of claims 1-3 and 11-13 of the '951 patent and claims 1-
3, 5-7, 10, 12, 18-20, and 22-25 of the '416 patent; and whether an
industry in the United States exists as required by subsection (a)(2)
of section 337; and
(b) Whether there is a violation of subsection (a)(1)(A) of section
337 in the importation into the United States, or in the sale of,
certain products identified in paragraph (2) by reason of false
designation of origin.
(2) Pursuant to section 210.10(b)(1) of the Commission's Rules of
Practice and Procedure, 19 CFR 210.10(b)(1), the plain language
description of the accused products or category of accused products,
which defines the scope of the investigation, is: Plant-derived
recombinant human serum albumins (``rHSA'') and products containing the
same, such as lyophilized powders and liquid suspensions primarily
containing rHSA along with naturally-occurring plant expression by-
products, such as plant heat shock proteins and/or plant fatty acids,
as well as cell culture media supplements formulated with such rHSA
products.
(3) For the purpose of the investigation so instituted, the
following are hereby named as parties upon which this notice of
investigation shall be served:
(a) The complainant is: Ventria Bioscience Inc., 2718 Industrial
Drive, Junction City, Kansas 66441.
[[Page 6917]]
(b) The respondents are the following entities alleged to be in
violation of section 337, and are the parties upon which the complaint
is to be served:
Wuhan Healthgen Biotechnology Corp., No. 666 Gaoxin Avenue, East Lake
High-Tech Development Zone, Wuhan, China, 430075
ScienCell Research Laboratories, Inc., 1610 Faraday Avenue, Carlsbad,
California 92008
Aspira Scientific, Inc., 521 Cottonwood Drive, Suite 112, Milpitas,
California 95035
eEnzyme LLC, 963 Featherstone Street, Gaithersburg, Maryland 20879
(c) The Office of Unfair Import Investigations, U.S. International
Trade Commission, 500 E Street SW, Suite 401, Washington, DC 20436; and
(4) For the investigation so instituted, the Chief Administrative
Law Judge, U.S. International Trade Commission, shall designate the
presiding Administrative Law Judge.
Responses to the complaint and the notice of investigation must be
submitted by the named respondent in accordance with section 210.13 of
the Commission's Rules of Practice and Procedure, 19 CFR 210.13.
Pursuant to 19 CFR 201.16(e) and 210.13(a), as amended in 85 FR 15798
(March 19, 2020), such responses will be considered by the Commission
if received not later than 20 days after the date of service by the
complainant of the complaint and the notice of investigation.
Extensions of time for submitting responses to the complaint and the
notice of investigation will not be granted unless good cause therefor
is shown.
Failure of the respondent to file a timely response to each
allegation in the complaint and in this notice may be deemed to
constitute a waiver of the right to appear and contest the allegations
of the complaint and this notice, and to authorize the administrative
law judge and the Commission, without further notice to the respondent,
to find the facts to be as alleged in the complaint and this notice and
to enter an initial determination and a final determination containing
such findings, and may result in the issuance of an exclusion order or
a cease and desist order or both directed against the respondent.
By order of the Commission.
Issued: January 15, 2021.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2021-01439 Filed 1-22-21; 8:45 am]
BILLING CODE 7020-02-P
